Trials / Completed
CompletedNCT02219178
Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Cancer Trials Ireland · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the overall response rate after 4 cycles and the best response to induction therapy with combination of lenalidomide, subcutaneous bortezomib, and dexamethasone (RsqVD) in patients with newly diagnosed multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lenalidomide | 25mg days 1 - 14 of 21 day schedule |
| DRUG | Subcutaneous bortezomib | 1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule |
| DRUG | Dexamethasone | 20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2019-10-31
- Completion
- 2020-04-01
- First posted
- 2014-08-18
- Last updated
- 2020-07-17
Locations
8 sites across 1 country: Ireland
Source: ClinicalTrials.gov record NCT02219178. Inclusion in this directory is not an endorsement.